Showing 2001-2010 of 2526 results for "".
- Eyenovia Announces Topline Results From VISION-1 Phase 3 Study of MicroLine for the Treatment of Presbyopiahttps://modernod.com/news/eyenovia-announces-positive-topline-results-from-vision-1-phase-3-clinical-study-of-microline-for-the-treatment-of-presbyopia/2479241/Eyenovia announced that its VISION-1 study evaluating the company’s proprietary pilocarpine formulation, MicroLine, for the temporary improvement of near vision in adults with presbyopia, achieved its primary endpoint. Preparations are underway for a second phase 3 registration study, VISION-2. T
- Why Can’t Americans Buy Contact Lenses From Vending Machines?https://modernod.com/news/why-cant-americans-buy-contact-lenses-from-vending-machines/2479238/A recent report in The Federalist details the ability to purchase contact lenses throughout most of Europe versus the United States, and the role regulatory agencies have in wh
- Scientists: New Research May Revolutionize Cataract Treatmenthttps://modernod.com/news/scientists-new-research-may-revolutionize-cataract-treatment/2479235/Eye experts have made a breakthrough that could potentially change the way cataracts are treated – with potential for drug therapy to replace surgery. A team of international scientists, led by Professor Barbara Pierscionek of Anglia Ruskin University (ARU), has published
- Eversight Awards 2020-2021 Eye & Vision Research Grantshttps://modernod.com/news/eversight-awards-2020-2021-eye-vision-research-grants/2479233/The Eversight Center for Vision and Eye Banking Research has awarded five grants to investigators at Harvard Medical School, University of Illinois College of Medicine, and Wayne State Universit
- The Children’s Eye Foundation of AAPOS Debuts “THE CURIOUS EYE” Interactive Storybookhttps://modernod.com/news/the-childrens-eye-foundation-of-aapos-debuts-the-curious-eye-interactive-storybook/2479230/The Children’s Eye Foundation of AAPOS unveiled the world’s first interactive children’s book to help screen for color vision deficiency (CVD), commonly known as color blindness. The foundation has posted a free digital version of THE CURIOUS EYE at
- Ocuphire Granted Two New US Patents Covering Late-Stage Drug Candidate Nyxol Including for the Treatment of Presbyopiahttps://modernod.com/news/ocuphire-granted-two-new-us-patents-covering-late-stage-drug-candidate-nyxol-including-for-the-treatment-of-presbyopia/2479225/Ocuphire Pharma announced that the United States Patent and Trademark Office (USPTO) has issued two patents covering the company’s late-stage product candidate, Nyxol (phentolamine mesylate). Both patents are directed to categories of subject matter eligible for listing in the U.S. FDA Orange Boo
- Rayner Receives FDA Approval for RayOne Spheric Monofocal IOLhttps://modernod.com/news/rayner-receives-fda-approval-for-rayone-spheric-monofocal-iol/2479221/Rayner has received FDA approval for the RayOne Spheric fully-preloaded monofocal IOL. The approval marks Rayner’s third FDA approval in under 3 years within its RayOne preloaded IOL portfolio. RayOne Spheric joins RayOne Aspheric (FDA approved December 2018) and RayOne EMV, a new non-diffractive
- Three Companies Combine to Form Corza Medicalhttps://modernod.com/news/three-companies-combine-to-form-corza-medical/2479217/Corza Medical, a provider of surgical products and technologies, was formed after uniting Surgical Specialties Corporation, Caliber Ophthalmics, and the TachoSil hemostatic patch device. &
- First Pediatric Patient with Rare Genetic Eye Disease Dosed in Clinical Trialhttps://modernod.com/news/first-pediatric-patient-with-rare-genetic-eye-disease-dosed-in-clinical-trial/2479207/ProQR Therapeutics has announced the first pediatric clinical trial participant has been treated in its new clinical trial named Brighten of the experimental RNA therapy sepofarsen. Brighten is a clinical study for children under 8 years old with Leber congenital amaurosis (LCA) d
- NUST MISIS Scientists Say They Developed a Safe Drug to Treat Eye Inflammationhttps://modernod.com/news/nust-misis-scientists-say-they-developed-a-safe-drug-to-treat-eye-inflammation/2479203/A Russian-American research team from The National University of Science and Technology MISIS has presented a new therapeutic method using nanoparticles of an antioxidant enzyme, developed specifically for the eyes. It relieves inflammation and repairs tissue without causing side effects: irritat